Lybrel-Birth-Control.com - Wyeth Pharmaceuticals News

Wyeth Pharmaceuticals News

Wedding: David T. McGovern and Laura E. Benoit Saturday, September 6, 2008 @ 11:03PMLaura E. Benoit of Skippack, daughter of Jack and Kathleen Benoit of Stuart, was married to David T. McGovern of Skippack on June 7 at Our Lady of the Snows Catholic Church in Woodstock, with the Rev. Tom L. Mosher officiating.
CYPHER® Sirolimus-eluting Coronary Stent Comparable To Bypass Surgery In Key Safety Measures In Patients With Diabetes ... Saturday, September 6, 2008 @ 2:12PMData from the largest randomized trial of its kind performed to date indicate that the use of percutaneous coronary intervention (PCI) with the CYPHER® Sirolimus-eluting Coronary Stent was comparable to bypass surgery (coronary artery bypass grafting or CABG) in key safety endpoints in patients with multi-vessel disease and diabetes.
Amgen And Wyeth Statement On The FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers Saturday, September 6, 2008 @ 1:12PMAmgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers [marketed as Remicade&r
Final Glance: Pharmaceuticals companies Friday, September 5, 2008 @ 5:25PMBristol-Myers Squibb fell $.01 or percent, to $21.49. Hospira fell $.43 or 1.1 percent, to $39.01.
FACTBOX-Drugs on U.S. FDA list for possible risks Friday, September 5, 2008 @ 1:01PMSept 5 (Reuters) - The U.S. Food and Drug Administration on Friday began issuing a list of drugs undergoing safety probes after the agency received reports of health problems.
Learn about the World CNS Therapeutics Market Thursday, September 4, 2008 @ 5:51PM Reportlinker.com announces that a new market research report related to the Neurology industry is available in its catalogue.
Final Glance: Pharmaceuticals companies Thursday, September 4, 2008 @ 5:09PMBristol-Myers Squibb fell $.04 or .2 percent, to $21.50. Hospira fell $.81 or 2.0 percent, to $39.44.
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers Thursday, September 4, 2008 @ 2:22PM THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.----Amgen and Wyeth Pharmaceuticals, a division of Wyeth , issued a statement in response to the Food and Drug Administration safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor blockers [marketed as Remicade® , Enbrel® , Humira® and Cimzia® ].
High Growth Forecasted for the In Vitro Diagnostics Market Report and Analysis 2008-2023 Thursday, September 4, 2008 @ 1:54PM Reportlinker.com announces that a new market research report related to the Medical devices industry is available in its catalogue.
Clinical Data Indicate that Percutaneous Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is ... Thursday, September 4, 2008 @ 1:00PM MUNICH----Data from the largest randomized trial of its kind performed to date indicate that the use of percutaneous coronary intervention with the CYPHER® Sirolimus-eluting Coronary Stent was comparable to bypass surgery in key safety endpoints in patients with multi-vessel disease and diabetes.
Get a Deep Insight Into The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023 Thursday, September 4, 2008 @ 10:05AM Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
My Pharmiweb.com Thursday, September 4, 2008 @ 4:29AMMadison, N.J., September 3, 2008 â€” Wyeth (NYSE:WYE) today announced the appointment of Daniel J. McIntyre, 54, to Vice President, Corporate Communications.
Heart Defibrillators Save Lives, Warn of Pending Risk in Study Thursday, September 4, 2008 @ 1:55AMSept. 4 (Bloomberg) -- A shock from a cardiac defibrillator is more than an immediate lifesaver for heart patients, a new study shows. It also can serve as an early warning system that their conditions may be deteriorating and the risk of death is on the rise.
Merck Serono and Ablynx Enter Into an Agreement to Co-Discover and Co-Develop Nanobodies(R) Thursday, September 4, 2008 @ 12:30AM Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that it has entered into an agreement with Ablynx , to co-discover and co-develop Nanobodies® against two targets in oncology and immunology.
Jolts from heart defibrillators often precede death Wednesday, September 3, 2008 @ 10:17PM A jolt from an implanted defibrillator is a very bad sign -- heart failure patients are about six times more likely to die after they receive their first life-saving shock, researchers reported on Wednesday.
Defibrillator Shocks Signal Increased Death Risk, Study Finds Wednesday, September 3, 2008 @ 5:19PMSept. 3 (Bloomberg) -- Heart failure patients who get a lifesaving shock from implanted cardiac defibrillators are five times as likely to die in the coming months and years, typically from progression of the disease, researchers said.
Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications Wednesday, September 3, 2008 @ 2:14PM Wyeth today announced the appointment of Daniel J. McIntyre, 54, to Vice President, Corporate Communications.
Expensive ads sell few prescription drugs: Study Monday, September 1, 2008 @ 8:41PMExpensive advertising of prescription drugs directly to consumers may do little to encourage sales, US and Canadian researchers reported on Monday.
Expensive ads sell few prescription drugs - study Monday, September 1, 2008 @ 6:01PMBy Maggie Fox, Health and Science Editor
METRO BUSINESS CALENDAR Sunday, August 31, 2008 @ 11:08PMCAREERS MONDAY, SEPT. 8 Career-Prospectors, www.career-prospectors.com, a job-search networking group, meets every Monday at 7:30 a.m., in the conference room at Long & Foster, 9321 Midlothian Turnpike. Details: Michael Soden, (804) 594-7065, or Fred Carreras, (804) 378-2021.
CYPHER Sirolimus-eluting Coronary Stent Outperforms The Taxus® Stent In People With Diabetes Saturday, August 30, 2008 @ 7:12AMIn patients with diabetes, the CYPHER® Sirolimus-eluting Coronary Stent outperformed the Taxus® Stent with significantly lower rates of in-segment restenosis (a reblockage within the stented area), target lesion revascularization (TLR; the need for another interventional procedure) and major
How to Play Biotech Without Getting Burned Friday, August 29, 2008 @ 2:00PM ETFs can offer the right prescription for targeting this volatile sector.
Exelixis Announces September 4 Webcast of Presentation at BioCentury´s NewsMakers in the Biotech Industry Conference Thursday, August 28, 2008 @ 3:05PMExelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, Executive Vice President and Chief
Midday Glance: Pharmaceuticals companies Thursday, August 28, 2008 @ 1:36PMBristol-Myers Squibb rose $.04 or .2 percent, to $21.56. Hospira rose $.57 or 1.4 percent, to $39.94.
Early Glance: Pharmaceuticals companies Thursday, August 28, 2008 @ 10:08AM(AP:NEW YORK) Shares of some top pharmaceuticals companies are mixed at 10 a.m.: Bristol-Myers Squibb fell $.04 or .2 percent, to $21.48. Hospira rose $.24 or .6 percent, to $39.61.
The CYPHER(R) Sirolimus-eluting Coronary Stent Outperforms the Taxus(R) Stent in People with Diabetes According to ... Thursday, August 28, 2008 @ 7:30AM WARREN, N.J.----In patients with diabetes, the CYPHER® Sirolimus-eluting Coronary Stent outperformed the Taxus® Stent with significantly lower rates of in-segment restenosis , target lesion revascularization and major adverse events at nine months according to clinical data appearing recently in the Journal of the American College of Cardiology.
2008 Breast Cancer Symposium Awards $14,000 To Oncology Fellows Thursday, August 28, 2008 @ 7:02AMOrganizers of the 2008 Breast Cancer Symposium announced the winners of the Symposium Merit Awards. Fourteen physicians-in-training will receive funding to assist with their travel to attend the Symposium, to be held September 5-7 in Washington, DC.
CME Outfitters Announces neuroscienceCME Webcast: "Depression as a Mind-Body Disorder in Minority Populations: Special ... Thursday, August 28, 2008 @ 2:01AM CME Outfitters announces an upcoming neuroscienceCME activity titled "Depression as a Mind-Body Disorder in Minority Populations:
Zealand Pharma today announced that Dr. David H Solomon has been appointed Chief Executive Officer Thursday, August 28, 2008 @ 12:00AM Today Zealand Pharma announced that Dr. David H Solomon has been appointed Chief Executive Officer. "We are delighted to have David as the new Chief Executive Officer. He brings more than 20 years of experience in medical research, healthcare investing and key biopharmaceutical and medical device operating roles," said Dr.
Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York Wednesday, August 27, 2008 @ 3:00PM Trubion Pharmaceuticals Inc. today announced that executives will present a corporate update at the upcoming Morgan Stanley Global Healthcare Unplugged Conference to be held at the Grand Hyatt New York on Sept. 9, 2008.
Midday Glance: Pharmaceuticals companies Wednesday, August 27, 2008 @ 12:30PMBristol-Myers Squibb fell $.68 or 3.1 percent, to $21.30. Hospira rose $.16 or .4 percent, to $39.29.
Teva Tells It Like It Is Wednesday, August 27, 2008 @ 11:53AMData from its Azilect trial looks as good as the top-line results.
CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Receives CE Mark Approval for Treatment of Heart Attacks Wednesday, August 27, 2008 @ 5:23AMCordis Corporation today announced that it has received CE mark approval to market the CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent for the treatment of acute myocardial infarction (AMI), more commonly known as a heart attack. CE mark approval means that the product has been deemed safe and effective for treatment of AMI and can now be promoted for this indication in all Member States ...
CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Receives CE Mark Approval for Treatment of Heart Attacks Wednesday, August 27, 2008 @ 5:00AM WARREN, N.J.----Cordis Corporation today announced that it has received CE mark approval to market the CYPHER SELECT® Plus Sirolimus-eluting Coronary Stent for the treatment of acute myocardial infarction , more commonly known as a heart attack.
Final Glance: Pharmaceuticals companies Tuesday, August 26, 2008 @ 4:58PMBristol-Myers Squibb unchanged at $21.98. Hospira rose $.39 or 1.0 percent, to $39.13.
Baxter Ready to Sop Up Additional Revenue Tuesday, August 26, 2008 @ 3:40PMThe health-care giant licenses a surgical sponge in clinical development.
Hedge Fund Giant SAC Bumps Up Stakes in Big Names Tuesday, August 26, 2008 @ 9:22AM Few hedge funds have the track record, heft, and name recognition of SAC Capital.
Final Glance: Pharmaceuticals companies Monday, August 25, 2008 @ 5:00PMBristol-Myers Squibb fell $.36 or 1.6 percent, to $21.98. Hospira fell $.32 or .8 percent, to $38.74.
Exelixis Announces September 3 Webcast of Presentation at the Thomas Weisel Partners 2008 Healthcare Conference Monday, August 25, 2008 @ 3:00PM SOUTH SAN FRANCISCO, Calif.----Exelixis, Inc. announced today that Frank Karbe, Executive Vice President and Chief Financial Officer of Exelixis, will present at the Thomas Weisel Partners 2008 Healthcare Conference at 10:20 a.m.
Insider Transactions Monday, August 25, 2008 @ 8:46AMSecurities trades recently reported to the Securities and Exchange Commission by officers, directors and principal shareholders of corporations based or having sizable employment in the Philadelphia area. Titles are as reported to the SEC.
Withdrawal: Drug industry jobs disappearing Sunday, August 24, 2008 @ 3:19AMOne of several people at the Dover unemployment office last week from the pharmaceutical industry, David Stern worked for a small company when layoffs hit a few months ago and a manager called him into an office.
Pharmaceutical job cuts in Morris region Saturday, August 23, 2008 @ 11:03PM• Abbott Laboratories: The company plans to close its manufacturing plant in Whippany, where 134 people work, by the end of the year. It recently agreed to sell the plant to another company, which will take over the building in December, according to Abbott Labs spokesman Kurt Ebenhoch.
Bancroft Fund Ltd. Announces Earnings and Financial Update Thursday, August 21, 2008 @ 12:07PM Bancroft Fund Ltd. today reported earnings, financial highlights and certain portfolio information for the nine months ended July 31, 2008:
Pipex Pharmaceuticals Acquires Late-Stage Oral Phase II Candidate For Rheumatoid Arthritis Thursday, August 21, 2008 @ 5:18AMPipex Pharmaceuticals, Inc.
An Essential Analysis and Forecast on Key Pricing and Reimbursement Trends for CNS Drugs Thursday, August 21, 2008 @ 4:54AM DUBLIN, Ireland----Research and Markets has announced the addition of Decision Resources, Inc.'s new report "SPECIAL REPORT: Key Pricing and Reimbursement Trends for CNS Drugs" to their offering.
Understand Obstetric & Gynecology Trends in the Use of Birth Control Devices Wednesday, August 20, 2008 @ 9:22AMResearch and Markets (http://www.researchandmarkets.com/research/c8be28/contraceptive_devi) has announced the addition of the "Contraceptive Devices: Where Are They Now? - Understanding Obstetric & Gynecology Trends in the Use of Birth Control Devices" report to their offering.
Research and Markets: Essential Chartbook of International Pharmaceutical Prices for 2008 from the Industry's Leaders Wednesday, August 20, 2008 @ 9:15AM DUBLIN, Ireland----Research and Markets has announced the addition of Decision Resources, Inc.'s new report "2008 Chartbook of International Pharmaceutical Prices" to their offering.
Understand Obstetric & Gynecology Trends in the Use of Birth Control Devices Wednesday, August 20, 2008 @ 9:00AM DUBLIN, Ireland----Research and Markets has announced the addition of the "Contraceptive Devices: Where Are They Now? – Understanding Obstetric & Gynecology Trends in the Use of Birth Control Devices" report to their offering.
A Comparative Analysis of Improving Professional Education Events for Ob/Gyn's Specializing in Birth Control Procedures Wednesday, August 20, 2008 @ 8:38AMResearch and Markets (http://www.researchandmarkets.com/research/4643be/contraceptive_devi) has announced the addition of the "Contraceptive Devices: Improving Professional Education Events for Ob/Gyn's Specializing in Birth Control Procedures" report to their offering.
A Comparative Analysis of Improving Professional Education Events for Ob/Gyn's Specializing in Birth Control Procedures Wednesday, August 20, 2008 @ 8:28AM DUBLIN, Ireland----Research and Markets has announced the addition of the "Contraceptive Devices: Improving Professional Education Events for Ob/Gyn's Specializing in Birth Control Procedures" report to their offering.